Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (301-310 of 345) with videos related to

Pageof 35
Sort By:
Seminars in Arthritis and Rheumatism|August 3, 2010
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesJeffrey R Curtis, Archana Jain, Johan Askling, et al.
The Journal of Rheumatology|June 19, 2012
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safetyClaire Bombardier, Glen S Hazlewood, Pooneh Akhavan, et al.
Inflammatory Bowel Diseases|January 9, 2007
Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's diseaseFrancesca Bresso, Johan Askling, Marco Astegiano, et al.
Scandinavian Journal of Public Health|December 9, 2024
Legal obstacles jeopardise research in personalised medicine - experiences from a Nordic collaboration within rheumatologyBente Glintborg, Mats Hansson, Hilde Berner Hammer, et al.
Pharmacoepidemiology and Drug Safety|August 26, 2015
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approachFredrik Nyberg, Johan Askling, Niklas Berglind, et al.
Rheumatology (Oxford, England)|December 28, 2020
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritisUlf Lindström, Bente Glintborg, Daniela Di Giuseppe, et al.
RMD Open|April 24, 2018
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic exampleKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Arthritis Care & Research|July 24, 2015
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational RegistriesSuzanne M M Verstappen, Johan Askling, Niklas Berglind, et al.
Rheumatology (Oxford, England)|June 28, 2020
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort studyRebekka Lund Hansen, Tanja Schoedt Jørgensen, Lene Dreyer, et al.
Annals of the Rheumatic Diseases|December 2, 2015
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registriesJohan Askling, Niklas Berglind, Stefan Franzen, et al.
Pageof 35

Showing results (301-310 of 345) with videos related to

Sort By:
Pageof 35
Seminars in Arthritis and Rheumatism|August 3, 2010
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesJeffrey R Curtis, Archana Jain, Johan Askling, et al.
The Journal of Rheumatology|June 19, 2012
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safetyClaire Bombardier, Glen S Hazlewood, Pooneh Akhavan, et al.
Inflammatory Bowel Diseases|January 9, 2007
Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's diseaseFrancesca Bresso, Johan Askling, Marco Astegiano, et al.
Scandinavian Journal of Public Health|December 9, 2024
Legal obstacles jeopardise research in personalised medicine - experiences from a Nordic collaboration within rheumatologyBente Glintborg, Mats Hansson, Hilde Berner Hammer, et al.
Pharmacoepidemiology and Drug Safety|August 26, 2015
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approachFredrik Nyberg, Johan Askling, Niklas Berglind, et al.
Rheumatology (Oxford, England)|December 28, 2020
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritisUlf Lindström, Bente Glintborg, Daniela Di Giuseppe, et al.
RMD Open|April 24, 2018
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic exampleKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Arthritis Care & Research|July 24, 2015
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational RegistriesSuzanne M M Verstappen, Johan Askling, Niklas Berglind, et al.
Rheumatology (Oxford, England)|June 28, 2020
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort studyRebekka Lund Hansen, Tanja Schoedt Jørgensen, Lene Dreyer, et al.
Annals of the Rheumatic Diseases|December 2, 2015
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registriesJohan Askling, Niklas Berglind, Stefan Franzen, et al.
Pageof 35